Could Intravenous Immunoglobulin Be an Elixir in Severe Acute Covid 19 with Secondary Infection

Abstract

On 21 December 2019, a pneumonia-like outbreak of an unknown cause or origin was found to be emerging in Wuhan, China. On 11 March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Though the pathology of COVID 19 is not yet fully understood, an immune-mediated inflammation is likely to play a role. In view of this, as in other viral infections, overactivation of the immune response was thought to play a major role in COVID 19 and anti-inflammatory drugs, immunomodulators, convalescent plasma, and antiviral drugs were used in the management. Morbidity and mortality in covid 19 are recently found to be increased by fungal co-infection. An agent of use in the setting of both acute covid 19 and mucormycotic that takes into account both infection and inflammation remains a clinical dilemma. Here we report one patient with severe COVID 19 pneumonia and rhinomucormycosis who received intravenous immunoglobulin and rhino nasal debridement with satisfactory recovery